Research & development

Two key products undergoing investigation in Europe as part of a global research program are Pemafibrate and Ripasudil:

Development Code / Nonproprietary NameClassificationIndicationsDevelopment Phase
PitavastatinHMG-CoA reductase inhibitorDyslipidemiaVietnam
Pitavastatin/
Ezetimibe
HMG-CoA reductase inhibitor/ NPC1L1 inhibitorDyslipidemia
PemafibrateSelective PPARa modulatorDyslipidemia


Non-alcoholic fatty liver


Primary biliary cholangitis




Malaysia
Singapore
Thailand







Pemafibrate/
Tofogliflozin
Selective PPARa modulator/ SGLT2 inhibitor
RipasudilRho kinase inhibitorGlaucoma and ocular hypertension


Fuchs endothelial corneal dystrophy






Vietnam








Ripasudil/
Brimonidine
Rho kinase inhibitor/Alpha-2 adrenergic receptor agonistGlaucoma and ocular hypertension
K-161Dry eye
IvermectinSARS-CoV-2 infections

Pipeline

Notes

  • Only a product in Clinical Stage is listed. This list does not include all of the products.
  • A product in Clinical Stage is defined as a product for which a regulatory procedure has been made for initiation of a first clinical trial (i.e. Investigational New Drug application in US, Clinical Trial Application in Europe, Clinical Trial Notification in Japan, or a similar process in other regions) and a regulatory procedure for discontinuation of development has not been made or regulatory approval has not been obtained in any regions where approval is anticipated.
  • A product assigned with International Nonproprietary Name (INN) is listed as its nonproprietary name. Otherwise, a development code is used.
  • This list shows the most advanced development phase for a product which is in more than one phase amongst countries and/or regions. In addition, countries and regions where regulatory application for marketing authorization (e.g. New Drug Application in US) has been filed with an approval yet to be granted, are also listed.
  • This list also includes a product in Clinical Stage for new indication(s) even if it has been already approved for different indication(s).

For more information on our research and development program visit https://www.kowa.co.jp/eng/business/health/development.html

Report adverse event

Kowa routinely monitors the safety of all its medicines. This includes review of safety data from clinical studies, and collection of reports and cases of adverse events for marketed products.

Patients and Volunteers in clinical trials reporting an adverse event must contact the investigator.

For specific medical information requests please visit the relevant product page to get in touch.

For the reporting of Livazo adverse events within Europe Union please contact local distributor or Recordati

For the reporting of Livazo adverse events within Middle East and North Africa (MENA) please contact...

Contact us












    I confirm I have read and accept the terms of the Privacy policy